View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
May 8, 2013

Shire signs rare disease discovery deal with Nimbus

Shire, the UK's third largest pharmaceutical firm, has teamed up with US-based Nimbus Discovery to develop small molecule treatments for rare genetic diseases.

By Nikitha Ladda

cell

Shire, the UK’s third largest pharmaceutical firm, has teamed up with US-based Nimbus Discovery to develop small molecule treatments for rare genetic diseases.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

The partners aim to develop the first small molecule agents designed to penetrate inaccessible tissues using Nimbus’ computational approach.

No financial details of the collaboration have been disclosed.

Shire is seeking small molecules from Nimbus against an undisclosed target associated with lysosomal storage disorders, a group of around 50 rare inherited metabolic disorders that result from defects in the lysosome – a specific organelle in the body’s cells.

In a statement, the companies said the collaboration is the result of a joint assessment of a series of rare disease targets "with significant unmet medical need [and] one target was ultimately chosen to be the research focus".

Nimbus said it will extensively profile molecules against the agreed-upon disease target and deliver a drug candidate that is ready to enter preclinical studies.

Nimbus CSO Dr Rosana Kapeller said; "This collaboration validates our computationally-driven, structure-based drug discovery engine and innovative partnering model.

"Nimbus is thrilled to pursue our first alliance with Shire , a company that shares our passion for uncovering breakthroughs in highly sought-after disease targets that have proven inaccessible to traditional industry approaches."

Shire will be responsible for all clinical development and future commercialisation activities.

Shire senior vice president for R&D Dr Philip Vickers said; "As a leader in rare diseases, this partnership is another way for Shire to ensure that we expand into new disease areas and continue to apply cutting-edge technologies in this space."


Image: Lysosomal storage disorders occur when a cell’s lysosome (12) malfunctions. Photo: Courtesy of Kelvinsong.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology